Basic information
Biomarker: EMA
Histology type: endometrial carcinoma
Cohort characteristics
Country: Spain
Region: Madrid
Study type: Comparative Study
Followed up time :
Subgroup 1 name : Overexpression in endometrial hyperplasias
Subgroup 1 number: 6
Subgroup 2 name: Low expression in endometrial hyperplasias
Subgroup 2 number: 34
| Total number | Group I | Group I number | Group II | Group II number | Group III | Group III number | Group IV | Group IV number |
|---|---|---|---|---|---|---|---|---|
| 178 | EC | 105 | endometrial hyperplasias | 40 | benign endometriums | 33 |
Sample information
Conclusion: EMA overexpression appears to be a marker of malignant transformation in the endometrium and it is an independent predictor of recurrent disease in endometrial cancer.
Sample type : tissue
Sample method: immunostaining
Expression pattern : overexpression
Expression elevation: Staining cell numbers were scored as none, weak (+, ,<33%), moderate (++, 33– 66%), and intense (+++, >66%). Overexpression was defined as intense staining. EMA immunostaining was observed in the apical membrane, cytoplasm, and luminal content.
Disease information
Related information
UniProt Link:
Molecular function from UniProt:
